![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NYAP2 |
Gene summary for NYAP2 |
![]() |
Gene information | Species | Human | Gene symbol | NYAP2 | Gene ID | 57624 |
Gene name | neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2 | |
Gene Alias | KIAA1486 | |
Cytomap | 2q36.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9P242 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57624 | NYAP2 | HCC1 | Human | Liver | HCC | 3.64e-19 | 1.25e+00 | 0.5336 |
57624 | NYAP2 | HCC2 | Human | Liver | HCC | 2.54e-34 | 1.88e+00 | 0.5341 |
57624 | NYAP2 | HCC5 | Human | Liver | HCC | 1.35e-37 | 1.66e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NYAP2 | SNV | Missense_Mutation | novel | c.523G>C | p.Ala175Pro | p.A175P | Q9P242 | protein_coding | tolerated(0.09) | benign(0.039) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
NYAP2 | SNV | Missense_Mutation | rs753236987 | c.197G>A | p.Arg66Gln | p.R66Q | Q9P242 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
NYAP2 | SNV | Missense_Mutation | novel | c.761N>C | p.Arg254Thr | p.R254T | Q9P242 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
NYAP2 | insertion | Frame_Shift_Ins | novel | c.965_966insATTTTTGA | p.Pro323PhefsTer53 | p.P323Ffs*53 | Q9P242 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
NYAP2 | insertion | Nonsense_Mutation | novel | c.966_967insCAATAGTGCTAACAGAGACTTTAGGTTTTTTTT | p.Ile322_Pro323insGlnTerCysTerGlnArgLeuTerValPhePhe | p.I322_P323insQ*C*QRL*VFF | Q9P242 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
NYAP2 | insertion | Nonsense_Mutation | novel | c.1011_1012insCGTGCTATTGTATGATGTCAGAAGTTTATGTTCT | p.Val338ArgfsTer5 | p.V338Rfs*5 | Q9P242 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | ||
NYAP2 | SNV | Missense_Mutation | novel | c.1729G>T | p.Ala577Ser | p.A577S | Q9P242 | protein_coding | tolerated_low_confidence(0.46) | benign(0.041) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NYAP2 | SNV | Missense_Mutation | novel | c.319C>A | p.Pro107Thr | p.P107T | Q9P242 | protein_coding | tolerated(0.21) | probably_damaging(0.998) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
NYAP2 | SNV | Missense_Mutation | c.590N>A | p.Arg197Gln | p.R197Q | Q9P242 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
NYAP2 | SNV | Missense_Mutation | c.590N>A | p.Arg197Gln | p.R197Q | Q9P242 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |